Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week
study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0
mg with a flexible dosing regimen in participants with neovascular age-related macular
degeneration previously treated with intravitreal anti-vascular endothelial growth factor
(VEGF) standard of care therapy. Only one eye will be chosen as the study eye.